Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences.
Hayes DF. Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences. Breast. 2015 Nov; 24 Suppl 2:S6-S10.